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FGender-Based Differences in the Inflammatory Profile of Peripheral
Arterial Disease and Their Association with Outcomes of Lower Ex-
tremity Vein Bypass Surgery
Jade S. Hiramoto, MD,a Christopher D. Owens, MD,a Ji Min Kim,a Michael
Belkin, MD,b Mark A. Creager, MD,b and Michael S. Conte, MD,a aDivi-
sion of Vascular Surgery, University of California – San Francisco, San
Francisco, Calif; and bBrigham and Womens Hospital, Boston, Mass.
Objective: To determine if there are gender-based differences in the
inflammatory phenotype of patients undergoing lower extremity bypass
(LEB) surgery and if they correlate with clinical outcomes.
Methods: Two hundred twenty-five patients (161 men and 64
women) underwent LEB using the autogenous vein between February 2004
and May 2008. Fasting baseline blood samples of inflammatory and pro-
thrombotic biomarkers were obtained before surgery. All patients under-
went ultrasound scan graft surveillance. High-sensitivity C-reactive protein
(CRP) levels were dichotomized at 5 mg/L, and fibrinogen levels were
dichotomized at 500 mg/dL. All patients were followed for a minimum of
1 year; median follow-up was 893 days (interquartile range [IQR], 539-
1315 days).
Results: There were no significant differences in age, race, hyperten-
sion, diabetes mellitus, and coronary artery disease between male and female
patients. Men were more likely to be smokers (P  .003), hyperlipidemic
(P .02), and taking statins (P .02). Women were more likely to present
with critical limb ischemia (P  .03) and had higher baseline CRP levels
(median, 5.15 mg/L; IQR, 1.51-18.62 mg/L) compared to men (median,
2.70; IQR, 1.24-6.98 mg/L; P  .03). In a multivariable analysis, female
gender (P  .03), hypertension (P  .01), estimated glomerular filtration
rate (eGFR; P .02), and critical limb ischemia (P .001) were associated
with log-transformed CRP levels. In a multivariable Cox Proportional
Hazards model for primary vein graft patency, there was a significant
interaction between both gender and CRP (P  .03) as well as gender and
fibrinogen (P  .08). Women with CRP 5 mg/L were significantly more
likely to lose primary vein graft patency compared to women with CRP 5
mg/L (P  .003), whereas there was no such difference seen in men (P 
.62). Women with fibrinogen 500 mg/dL were also more likely to lose
primary graft patency compared to women with fibrinogen 500 mg/dL
(P  .04), but again, this pattern was not evident in men (P  .66).
Conclusions: Women undergoing LEB for advanced peripheral arte-
rial disease (PAD) have an elevated inflammatory phenotype compared to
men. Elevated baseline levels of CRP and fibrinogen are associated with
inferior vein graft patency in women, but not in men. These findings suggest
an important interaction between gender and inflammation in the healing
response of lower extremity vein bypass grafts.
Viabahn Treatment for Femoropopliteal Occlusive Disease: Relation-
ship between Implant Length and Clinical Outcomes
Paul C. Johnston, MD,a,b Sara J. Runge, MD,c Linda M. Reilly, MD,c Jade
S. Hiramoto, MD,c Charles M. Eichler, MD,c Christopher M. Owens, MD,c
Darren B. Schneider, MD,c,d and Michael S. Conte, MD,c aDepartment of
Vascular Surgery, University of California San Francisco, San Francisco,
Calif; bDepartment of Vascular Surgery, Kaiser Permanente Medical
Group, Denver, Colo; cUniversity of California San Francisco, San
Francisco, Calif; and dColumbia–Cornell University, New York, NY.
Objective: Optimal patient selection for revascularization approaches
in femoropopliteal occlusive disease (FPOD) remains controversial. Cov-
ered stent placement in the femoropopliteal (FP) segment has become
increasingly prevalent. There is little information regarding the influence of
implant length on the clinical performance of these devices.
Methods: This was a retrospective, single-center study of 89 consecu-
tively treated limbs (78 patients) that underwent Viabahn stent graft place-
ment for FPOD from 2005 to 2010. Procedures were dichotomized accord-
ing to the total length of the implanted devices using a cutpoint of 20 cm.
Freedom from reintervention, thrombolysis, open bypass surgery, and com-
posite major adverse limb events (MALEs  major amputation, thrombol-
ysis/thrombectomy, or open bypass surgery) were compared by log-rank
analysis. Logistic regression was used to model clinical endpoints.
Results: Thirty-eight percent of grafts were placed for critical limb
ischemia (CLI), 51% in diabetics, and 31% were reinterventions. Total
implant length was 20 cm in 55 patients (62%). Estimated 1-year event
rates for the two groups (20 cm) were as follows: any reintervention (40% vs
50%; P .7), thrombolysis (0% vs 27%; P .014), open bypass (13% vs 22%;
P  .33), and MALE (14% vs 35%; P  .068). Implant length was
independently predictive of need for thrombolysis (P  .01) and MALE
p
p
586P  .053) on multivariate logistic regression. Indication (claudication vs
LI) was not predictive of thrombolysis or MALE.
Conclusions: Rates of reintervention after Viabahn treatment for
POD are considerable. The risk of MALEs is strongly associated with total
mplant length and is driven by thrombolysis. These data have implications
or surgical decision-making in FPOD.
omparing Patency and Salvage Rates between Multiple Ipsilateral
liac Artery Stents and Isolated Iliac Artery Stents: Beyond Trans-
tlantic Inter-Society Consensus II
achel C. Danczyk, MD, Erica L. Mitchell, MD, Sharon G. Kryger, Chad
urk, Sarguni Singh, Timothy K. Liem, MD, Gregory J. Landry, MD, James
. Edwards, MD, Bryan D. Petersen, MD, and Gregory L. Moneta, MD,
ivision of Vascular Surgery, Oregon Health and Science University, Port-
and, Ore.
Objectives: Endovascular stents are accepted therapy for TransAtlantic
nter-Society Consensus (TASC) A, B, and some C lesions. Surgery is the
ecommended therapy for patients with TASC D lesions, including those
ith both ipsilateral common iliac artery (CIA) and external iliac artery
EIA) stenoses/occlusion. This study compares anatomic patency and op-
rative salvage rates for combined ipsilateral CIA and EIA stenting (TASC
) vs CIA or EIA stents alone (TASC A, B, or C).
Methods:All patients (n 588) who underwent iliac artery stenting at
wo institutions between 1998 and 2010 were identified. Patient comorbidi-
ies and outcomes were retrospectively reviewed and analyses were per-
ormed using multivariate regression and Kaplan-Meier methods.
Results: There were 436 extremities with CIA stents, 195 with EIA
tents, and 157 with both CIA and EIA stents. There was no significant
ifference in demographics, comorbidities, or treatment indications be-
ween groups. During follow-up, 183 patients died, 95 underwent endovas-
ular reintervention, and 48 required salvage operation. Mean times to
ollow-up, death, reintervention, and operative salvage were 2.2  0.1,
.6  0.3, 7.2  0.6, and 9.6  0.5 years, respectively. CIA and EIA
tenting in combination was not a predictor of death, reintervention, or
alvage operation. Survival, reintervention-free survival, and salvage opera-
ion-free survival were similar between those who had CIA or EIA stents
lone and those with both CIA and EIA stents (all P  .05).
Conclusions: CIA stents, EIA stents, and the combination of ipsilat-
ral CIA and EIA stents have similar outcomes. Salvage operations for iliac
rtery stent failure are uncommon and not influenced by the location or
xtent of iliac artery stent placement. This study suggests that a more
ggressive approach with total endovascular management for some TASC D
esions is acceptable. TASC II recommendations for endovascular therapy
or aortoiliac disease should be extended to consider selected patients with
psilateral CIA and EIA stenoses/occlusion.
he Number of Patent Tibial Vessels does not Influence Primary
atency after Nitinol Stenting of the Femoral and Popliteal Arteries
enny Lee, MD,c and Steven G. Katz, MD,a,b aDepartment of Vascular
urgery, University of Southern California Surgeons, bthe Department of
edical Education, Huntington Hospital, and cthe Department of Surgery,
untington Hospital, Pasadena, Calif.
Objective: Initial TransAtlantic Inter-Society Consensus (TASC) II
lassification has been shown to influence the patency of stented femoral and
opliteal arteries. While several studies have shown the effect of the number
f runoff vessels on the durability of infrainguinal angioplasty without
tenting, the influence of tibial vessel runoff on the patency of primarily
tented femoral and popliteal arteries has not been as well defined. It is the
urpose of this study to determine whether the number of patent tibial
essels affects primary patency after primary stenting of the femoral and
opliteal arteries.
Methods: The medical records of all patients undergoing angioplasty
nd primary nitinol stenting of the femoral and popliteal arteries by or under
he supervision of a single vascular surgeon were reviewed. Results were
nalyzed by the number of patent tibial vessels documented on periproce-
ural angiography and TASC II classification. KaplanMeier survival curves
ere plotted and differences between groups tested by log-rank method.
isher’s exact and 2 tests were used to compare categorical factors.
Results: During a 7-year period, 316 limbs in 262 patients underwent
rimary stenting of the femoral and popliteal arteries. Overall primary
atency was 71% at 12 months, 51.6% at 24 months, and 39.5% at 36
